Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PainReform Ltd. stock logo
PRFX
PainReform
$1.32
-7.7%
$1.62
$1.25
$16.63
$2.66M0.57271,431 shs139,469 shs
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
$0.00
$0.00
$0.00
$0.42
$16.54M2.25511,766 shs488,692 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.18
-40.4%
$0.49
$0.20
$3.10
$3.08M0.92284,137 shs3.73 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$4.85
+0.3%
$4.93
$0.13
$1.04
$93.40M1.581.05 million shs4,239 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PainReform Ltd. stock logo
PRFX
PainReform
0.00%-11.41%-7.95%-44.07%-18.42%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.00%+7.14%+7.14%+66.67%-87.50%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%-39.32%-84.02%-88.30%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
+0.31%+1.68%+0.41%-3.39%+2,198.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
PainReform Ltd. stock logo
PRFX
PainReform
0.2618 of 5 stars
0.02.00.00.00.01.70.6
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
4.0378 of 5 stars
3.35.00.04.70.60.01.3
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PainReform Ltd. stock logo
PRFX
PainReform
2.00
HoldN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.00
N/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
2.50
Moderate Buy$3.751,994.97% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.00
Hold$5.003.09% Upside

Current Analyst Ratings Breakdown

Latest SRNEQ, UBX, PRFX, and VIRI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$4.00 ➝ $2.00
5/16/2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$6.00 ➝ $1.00
(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/A$2.08 per shareN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
$62.84M0.01N/AN/A($0.05) per share-0.03
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/A$0.39 per shareN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PainReform Ltd. stock logo
PRFX
PainReform
-$14.59M-$147.33N/AN/AN/AN/AN/A8/21/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%8/5/2025 (Estimated)
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)

Latest SRNEQ, UBX, PRFX, and VIRI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$0.30N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PainReform Ltd. stock logo
PRFX
PainReform
N/A
1.81
1.81
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/A
1.95
1.95
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
PainReform Ltd. stock logo
PRFX
PainReform
37.28%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.02%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
29.49%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
2.60%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
5.80%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
PainReform Ltd. stock logo
PRFX
PainReform
42.01 million1.32 millionNot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
800551.28 million536.95 millionNot Optionable
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
6017.21 million16.21 millionOptionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable

Recent News About These Companies

Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
Dogwood Therapeutics faces potential Nasdaq delisting
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
DWTX: Phase 2 Long COVID Results Expected Soon
Dogwood Therapeutics Reports Q3 2024 Financial Results
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

PainReform stock logo

PainReform NASDAQ:PRFX

$1.32 -0.11 (-7.69%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.30 -0.03 (-1.89%)
As of 08/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Sorrento Therapeutics stock logo

Sorrento Therapeutics OTCMKTS:SRNEQ

$0.0015 0.00 (0.00%)
As of 08/1/2025

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

UNITY Biotechnology stock logo

UNITY Biotechnology NASDAQ:UBX

$0.18 -0.12 (-40.43%)
Closing price 07/8/2025
Extended Trading
$0.18 0.00 (0.00%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$4.85 +0.02 (+0.31%)
As of 08/1/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.